NKTR vs VOR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NKTR Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nektar Therapeutics (NKTR) driven by superior Valuation, Options & Structure while VOR counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, NKTR trades at 34.0x Forward P/E with -239.3% operating margin (-9.3% YoY revenue) versus VOR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NKTR sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro) against VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NKTR | VOR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $1.2B | Larger Scale | NKTR |
| Trailing P/E Ratio Valuation | 34.0x | 0.1x | Lower Multiple | VOR |
| Forward P/E Ratio Valuation | 34.0x | N/M | Lower Multiple | NKTR |
| Revenue Growth (YoY) Growth | -9.3% | +0.0% | Higher Growth | VOR |
| Operating Margin (TTM) Profitability | -239.3% | 0.0% | Higher Margin | VOR |
| Net Profit Margin Profitability | -287.8% | 0.0% | Higher Margin | VOR |
| Return on Equity (ROE) Capital Efficiency | -35.8% | -125.4% | Higher ROE | NKTR |
| 52-Week Range Position Momentum | 4% ($33โ$109) | 65% ($6โ$26) | Stronger Trend | VOR |
| Beta / 30D Volatility Risk Regime | 1.10ฮฒ ยท 48% Vol | 1.91ฮฒ ยท 61% Vol | Lower Realized Risk | NKTR |
| Unified Institutional Score Composite Signal | 61.1 / 100 (BUY) | 57.8 / 100 (HOLD) | Higher Composite | NKTR |